Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Doctors say lowering age cutoff for AstraZeneca vaccine makes sense as cases surge

04/16/2021 | 05:39pm EDT

CALGARY — Doctors say the Oxford-AstraZeneca vaccine should be offered to Canadians in a wider age range as COVID-19 infections soar in many parts of the country.

Provinces limited eligibility for that vaccine to those 55 and older after a small number of cases of an unusual and serious blood-clotting condition appeared in younger people — mostly women — who had received a shot.

The odds of someone getting the syndrome — dubbed vaccine-induced immune thrombotic thrombocytopenia — has been estimated at between one in 100,000 and one in 250,000.

By comparison, about one in four people hospitalized with COVID-19 will experience a blood clot, Alberta's chief medical officer of health Dr. Deena Hinshaw noted this week.

"Certainly based on risks, most people are much better off with a vaccine," said Dr. Daniel Gregson, an associate professor at the University of Calgary's Cumming School of Medicine.

"You can certainly drop it easily to 45, if not 35."

Gregson, who specializes in infectious diseases and medical microbiology, said uncertainty has been planted in peoples' minds about getting AstraZeneca, but they do things that are just as risky on a daily basis without a second thought.

Dr. Susy Hota, medical director of infection prevention and control at Toronto's University Health Network, said she would also support dropping the age limit, so long as no other worrying side-effects arise and recipients are aware of the risk, however small.

"I think it's an important strategy we need to consider," said Hota, also an associate professor of infectious diseases at the University of Toronto.

"The case counts are going up too fast and they're going to a point where it's hitting the hospitals in a way that we've not experienced before, ever."

Hota suggested one approach could be offering the shot to younger men, since the rare side-effect seems to be more prevalent in women.

Health Canada has deemed the AstraZeneca vaccine safe, saying the benefits outweigh the risks.

The National Advisory Committee on Immunization has not yet changed its recommendation that the shot only be offered to those 55 and up, but the decision ultimately rests with provinces.

In Quebec, where AstraZeneca is available to those between the ages of 55 and 79, Health Minister Christian Dube said provincial public health authorities were considering whether to expand access.

Alberta is also considering a change, Hinshaw said.

"I also know that some who are younger than 55 are interested in getting the protection that this vaccine offers," she said Thursday.

"Given the Health Canada assessment, we will be discussing this question with our Alberta Advisory Committee on Immunization this week to get their perspective."

In the meantime, Hinshaw is urging anyone who is already eligible to get their AstraZeneca dose without delay.

Walk-in vaccinations are available at 26 pharmacies in Calgary and Edmonton and Alberta Health Services is opening walk-in vaccination clinics this weekend in both cities.

"While not getting vaccinated may feel like a way to protect your health by avoiding the rare risk of a blood clot following vaccine, waiting can actually increase your risk of getting sick, or worse," Hinshaw said.

This report by The Canadian Press was first published on April 16, 2021.

© 2021 The Canadian Press. All rights reserved., source Canadian Press DataFile

All news about ASTRAZENECA PLC
04:52pASTRAZENECA  : New Brunswick reports two more cases of rare blood-clotting event..
AQ
02:48pASTRAZENECA  : Ontario keeps stay-at-home order; Quebec pauses Oxford-AstraZenec..
AQ
12:12pASTRAZENECA  : Egypt receives 2.2 mln AstraZeneca and Sinopharm vaccine doses
RE
11:41aMODERNA  : Quebec stops Oxford-AstraZeneca as a first dose, reports 781 new COVI..
AQ
09:01aTop scientists question the need for COVID-19 booster shots
RE
08:49aRBC on Bank of Canada's Governor Scheduled Speech Thursday; Notes COVID-19 Up..
MT
07:02aASTRAZENECA  : New Tezepelumab Data Continue to Strengthen Profile for a Broad P..
BU
06:06aASTRAZENECA  : Covid-19 - Over 15,000 People Take First Jab of Astrazeneca
AQ
05:45aInside the Hunt for a Link Between Some Covid-19 Vaccines and Rare Blood Clot..
DJ
04:49aOROPHARYNGEAL CANCER PIPELINE : Emerging Therapies and Key pharma players involv..
AQ
More news
Financials (USD)
Sales 2021 31 204 M - -
Net income 2021 4 488 M - -
Net Debt 2021 10 883 M - -
P/E ratio 2021 32,5x
Yield 2021 2,59%
Capitalization 145 B 145 B -
EV / Sales 2021 4,99x
EV / Sales 2022 4,40x
Nbr of Employees 76 100
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Average target price 130,37 $
Last Close Price 110,29 $
Spread / Highest target 50,5%
Spread / Average Target 18,2%
Spread / Lowest Target -12,7%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC6.31%144 070
JOHNSON & JOHNSON6.88%442 937
ROCHE HOLDING AG-2.57%286 340
PFIZER, INC.6.90%221 397
ABBVIE INC.7.29%203 045
NOVARTIS AG-4.30%197 785